An Ipca Labs plant savaged in an FDA warning letter three years ago continues to fail manufacturing standards that would assure its drugs are safe.
Two C-level execs, including one who's under blame for an FDA warning letter, will leave Bayer first thing next year.
Private equity investor Advent International has picked up another piece of Sanofi that the French drugmaker is shedding.
Catalent has invested $9 million in a clinical supply facility and Sagent has access to expanded manufacturing in Canada.
Troubled Mallinckrodt is selling sell its CDMO unit for up to $250 million, but that is a drop in the bucket of what it may need going forward.
Aurobindo has been repeatedly knocked by the FDA, and now a mislabeling snafu is pulling more of the drugmaker’s generics off U.S. shelves.
Takeda is having to recall the Natpara from the market, a move it says may be very challenging for patients.
Will your blood pressure meds give you cancer? Probably not, the FDA says.
A Novartis ingredient operation in China is being hived off as the Swiss drugmaker continues its drive to cut manufacturing jobs.
The clock is ticking down for the 400 workers at a Novartis plant which was put on the block last year as the company cuts costs to finance new therapies.
